Effects of alendronate on bone loss in pre- and postmenopausal hyperthyroid women treated with methimazole

被引：23

作者：

Lupoli, G ^{[1
]}

Nuzzo, V ^{[1
]}

DiCarlo, C ^{[1
]}

Affinito, P ^{[1
]}

Vollery, M ^{[1
]}

Vitale, G ^{[1
]}

Cascone, E ^{[1
]}

Arlotta, F ^{[1
]}

Nappi, C ^{[1
]}

机构：

[1] UNIV NAPLES FEDERICO II,DEPT MOL & CLIN ENDOCRINOL & ONCOL,NAPLES,ITALY

来源：

GYNECOLOGICAL ENDOCRINOLOGY | 1996年 / 10卷 / 05期

关键词：

hyperthyroidism; osteoporosis; biphosphonate; osteocalcin; bone mineral density;

D O I：

10.3109/09513599609012821

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

High levels of thyroid hormones accelerate bone turnover. The aim of the present study was to evaluate the effects of treatment with alendronate in patients affected by hyperthyroidism and osteoporosis. We studied 40 hyperthyroid patients with bone loss, divided into two groups according to menopausal state. Before treatment and after 6 and 12 months, serum 1 thyroid hormones levels, sevum osteocalcin level and bone mineral density were evaluated. In all patients we observed an increase in bone mineral density after treatment with alendronate, and a corresponding decrease in serum osteocalcin level.

引用

页码：343 / 348

页数：6

共 38 条

[1]

ADAMI S, 1993, OSTEOPOROSIS INT, V3, pS21

[2]

AITKEN JM, 1973, BRIT MED J, V1, P325

[3]

BAYLEY TA, 1980, J CLIN ENDOCR METAB, V50, P916, DOI 10.1210/jcem-50-5-916

[4]

BOONEKAMP PM, 1986, BONE MINER, V1, P27